Media Summary: Heart Failure Guidelines - Prof. John Mcmurray - 5th Annual ESMA Conference 2023 May 2018, Toronto: This presentation was part of This film explores the incredible contribution

Professor John Mcmurray Heart Failure Therapy Extending The Limits - Detailed Analysis & Overview

Heart Failure Guidelines - Prof. John Mcmurray - 5th Annual ESMA Conference 2023 May 2018, Toronto: This presentation was part of This film explores the incredible contribution New Era and New Guidelines. Grand Rounds with: Michael McDonald, MD Associate Clinical Trials Masterclass - Third lecture. Supported by the German Center for Having 2 trials that both show benefits of SGLT2 inhibitors in

Dapagliflozin was shown to not only benefit patients at risk of Inhibitors of sodium–glucose cotransporter 2 (SGLT2) are known to improve

Photo Gallery

Professor John McMurray - Heart failure therapy – extending the limits!
Professor John McMurray - Heart failure: pharmacology that extends the limits!
Professor Theresa McDonagh - Heart failure therapy – extending the limits!
Novel developments in the treatment of HFREF - Prof. Dr. John McMurray (Glasgow, UK)
Professor Theresa McDonagh - Heart failure therapy – extending the limits!
Heart Failure Guidelines - Prof. John Mcmurray - 5th Annual ESMA Conference 2023
Heart failure therapeutics: the ultimate pharmacological success story? - John McMurray
Dr. John McMurray: New and emerging heart failure therapies
Legacy of a Pioneer: Prof John McMurray
Dr John McMurray Explains the Heart Failure Benefits of Dapagliflozin in Diabetics and Non-Diabetics
Prof. John McMurray | EMPEROR Preserved trial
Dr John McMurray: The Next Step for SGLT 2 Inhibitors in Patients with HF Is Implementation
View Detailed Profile
Professor John McMurray - Heart failure therapy – extending the limits!

Professor John McMurray - Heart failure therapy – extending the limits!

Heart failure therapy

Professor John McMurray - Heart failure: pharmacology that extends the limits!

Professor John McMurray - Heart failure: pharmacology that extends the limits!

Professor John McMurray

Professor Theresa McDonagh - Heart failure therapy – extending the limits!

Professor Theresa McDonagh - Heart failure therapy – extending the limits!

Professor

Novel developments in the treatment of HFREF - Prof. Dr. John McMurray (Glasgow, UK)

Novel developments in the treatment of HFREF - Prof. Dr. John McMurray (Glasgow, UK)

Prof

Professor Theresa McDonagh - Heart failure therapy – extending the limits!

Professor Theresa McDonagh - Heart failure therapy – extending the limits!

Professor

Heart Failure Guidelines - Prof. John Mcmurray - 5th Annual ESMA Conference 2023

Heart Failure Guidelines - Prof. John Mcmurray - 5th Annual ESMA Conference 2023

Heart Failure Guidelines - Prof. John Mcmurray - 5th Annual ESMA Conference 2023

Heart failure therapeutics: the ultimate pharmacological success story? - John McMurray

Heart failure therapeutics: the ultimate pharmacological success story? - John McMurray

So thank you

Dr. John McMurray: New and emerging heart failure therapies

Dr. John McMurray: New and emerging heart failure therapies

May 2018, Toronto: This presentation was part of

Legacy of a Pioneer: Prof John McMurray

Legacy of a Pioneer: Prof John McMurray

This film explores the incredible contribution

Dr John McMurray Explains the Heart Failure Benefits of Dapagliflozin in Diabetics and Non-Diabetics

Dr John McMurray Explains the Heart Failure Benefits of Dapagliflozin in Diabetics and Non-Diabetics

In patients with

Prof. John McMurray | EMPEROR Preserved trial

Prof. John McMurray | EMPEROR Preserved trial

John McMurray

Dr John McMurray: The Next Step for SGLT 2 Inhibitors in Patients with HF Is Implementation

Dr John McMurray: The Next Step for SGLT 2 Inhibitors in Patients with HF Is Implementation

It's a great time to be a doctor

Results of DAPA-HF - Dr. John J McMurray

Results of DAPA-HF - Dr. John J McMurray

John

Updated pharmacologic therapy for heart failure with reduced ejection fraction

Updated pharmacologic therapy for heart failure with reduced ejection fraction

New Era and New Guidelines. Grand Rounds with: Michael McDonald, MD Associate

Prof. John McMurray - What have we learned from the SGLT2i trials in heart failure?

Prof. John McMurray - What have we learned from the SGLT2i trials in heart failure?

Clinical Trials Masterclass - Third lecture. Supported by the German Center for

Dr John McMurray Compares EMPEROR-Reduced Findings with DAPA-HF

Dr John McMurray Compares EMPEROR-Reduced Findings with DAPA-HF

Having 2 trials that both show benefits of SGLT2 inhibitors in

Finerenone In Heart Failure W/ Mildly Reduced and Preserved Ejection Fraction:FINEARTS-HF in Context

Finerenone In Heart Failure W/ Mildly Reduced and Preserved Ejection Fraction:FINEARTS-HF in Context

Date: 10 Feb 2025 Speaker:

Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure

Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure

Dapagliflozin was shown to not only benefit patients at risk of

Implementing Quadruple Medical Therapy for Heart Failure with Reduced Ejection Fraction

Implementing Quadruple Medical Therapy for Heart Failure with Reduced Ejection Fraction

An expert review of quadruple

SGLT2 Inhibitors in Heart Failure Management with Dr. John McMurray

SGLT2 Inhibitors in Heart Failure Management with Dr. John McMurray

Inhibitors of sodium–glucose cotransporter 2 (SGLT2) are known to improve